Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Manufacturing

CAR-T Therapies: Failure To Meet Release Specifications May Not Bar Patient Use

Some patients in Novartis' pediatric leukemia pivotal trial for tisagenlecleucel (CTL019) received out-of-spec product following the sponsor's consultation with US FDA, and the same thing might occur in the commercial setting.

Advisory Committees Drug Review Manufacturing

Latest From Manufacturing

Trump Lauds Big Pharma Collaboration On Super Strong Glass Packaging

President announces Merck, Pfizer and Corning collaboration on new glass packaging for injectable drugs as part of "Made In America Week;" says FDA is streamlining regulations.

BioPharmaceutical Commercial

FDA Announces Plans To Develop Supply Chain Security Pilot Program

FDA has announced its intent to establish a supply chain pilot program with the input of the pharmaceutical industry and is holding three upcoming meetings on supply chain security.

Manufacturing Quality

FDA's Kopcha Presses Ahead On Quality Metrics Despite Industry Pushback

The head of US FDA's drug quality office, Michael Kopcha, rebukes industry pushback that got White House's ear and demands more constructive feedback on quality metrics. Industry workshop participants come up with creative ideas, but FDA finds them problematic. Asked whether industry should dive in or wait and see on voluntary phase of metrics initiative that begins in January, another FDA official says, "That's a tough one."

Manufacturing Quality

India Mulls Contentious Move To All ‘Vegetarian’ Pharma Capsules

India, one of the largest generic drug producers globally, is considering banning animal-origin gelatin capsules to respect the “religious sentiments” of the large number of Indians who are vegetarian, but groups are raising objections.

India Manufacturing

EU Officials Note Similarities In Post-Approval Changes For Biosimilars, Reference Drugs

EU pharmaceutical and industry officials note some common trends and similarities in post-approval changes for biosimilars and reference products. One vexing problem in instituting post-approval changes is whether to use the reference drug or the approved biosimilar and regulatory guidance in this area is lacking.

Biosimilars Manufacturing

FDA Funding Bill Clears House Cmte., Defers Action On Compounding

Measure to provide $5.2b to FDA in FY 2018; amendment on office-use compounding withdrawn after House Appropriations Committee agrees to work to get FDA to allow practice.

FDA Legislation
See All